Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10524484	
INFORMATION DISCLOSURE	Filing Date		2005-02-14	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Glen	en Ernst	
(Not for submission under 37 CFR 1.99)	Art Unit		1624	
(Not for Submission under or or K 1.50)	Examiner Name	Brend	da Libby Coleman	
	Attorney Docket Number	er	100793-1P-US	

U.S.PATENTS										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C	Date	Name of Patentee or Applicant of cited Document		Relev	s,Columns,Lines where vant Passages or Relev es Appear	
/B.C./	1	3281423		1996-10	0-25	Rogers, et. al				
/B.C./	2	5679673		1997-10	0-21	Bowen, et al.				
If you wis	h to ac	⊥ dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
/B.C./	1	20070244097		2007-10	0-18	Glen Ernst, et al.				
If you wish to add additional U.S. Published Application citation information please click the Add button.										
				FOREIG	GN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
/B.C./	1	1231212	EP			2002-08-14 Pfizer Products, Ind		 с.		
/B.C./	2	2004016616	WO			2004-02-26	1-02-26 AstraZeneca AB			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10524484
Filing Date		2005-02-14
First Named Inventor Glen		Ernst
Art Unit		1624
Examiner Name	Brend	da Libby Coleman
Attorney Docket Number		100793-1P-US

/B.C./	3	2004016617	wo		2004-02-26	AstraZeneca AB			
/B.C./	4	1219622	EP		2002-07-03	Pfizer Products Inc.			
** /B.C./	5	6501367	NL		1965-08-04	Merck & Co., Inc.			
** /B.C./	6	0058311	WO		2000-10-05	Sanofi-Synthelabo			
If you wis	h to ac	dd additional Foreign Pa				ease click the Add buttor	1	•	
	ı	Γ			RATURE DO				
Examiner Initials*	Cite No	TOOOK magazine jojirnai seriai symnosiiim gatalog etg) gate nages(s) yojijme-issije niimper(s) — 1 15							
/B.C./	/B.C./ 1 PFIZER, INC., "Preparation of diazabicyclononanes as intermediates for anitbacterial quinolones, & USA 4895943, 19900123" STN International, file CAPLUS, CAPLUS accession no. 1990:423956 document no. 113:23956, 1990.								
/B.C./ 2 MERCK & CO., "1,3-Ethanopiperazine and derivatives and NL, 65001367, 19650804," STN International, file CAPLUS, CAPLUS accession no. 1966:27623, document no. 64:27623, 1996.									
RUBSTOV, M.V. et al, "Beckmann rearrangement in the heterocyclic series. Rearrangement of oximes of 3-quinuclidone and 1-azabicyclo[3.2.1]6-octanone and Zh. Obshch. Khim. (1964), 34(7),2222-6," STN International, file CAPLUS, CAPLUS accession no. 1964:454808, document no 61:54808.									
/B.C./	4	4 Copy of March 03, 2008 Office Action from US serial no. 10/524,482 (US2006/0052368)							
If you wish to add additional non-patent literature document citation information please click the Add button									

** STRUCTURES ONLY

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10524484	
Filing Date		2005-02-14	
First Named Inventor	Glen	Ernst	
Art Unit		1624	
Examiner Name	Brend	da Libby Coleman	
Attorney Docket Number		100793-1P-US	

EXAMINER SIGNATURE						
Examiner Signature	06/25/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.						